Access to biologics for rheumatoid arthritis varies widely in Europe
This article was originally published in Scrip
Executive Summary
There are large inequalities in access to innovative biologic rheumatoid arthritis (RA) treatments across Europe, says a new study published in the European Journal of Health Economics. Variations in drug affordability, standardised prices and health technology assessments all take their toll on uptake to varying degrees.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.